In contrast to the divergent results we observed with CSP mAbs, a study of protection from influenza by therapeutic mAbs reported similar loss of protection in FcgR-binding-ablated GRLR variants of three distinct mAbs that bind either influenza HA or NA protein (18). This evidence concerns the gene DNAJC5 and influenza.